Live price temporarily unavailable.
United Therapeutics (UTHR) is a Health Care company in the Russell 1000. Latest news and coverage below.
United Therapeutics revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.60B | $1.73B | $1.63B | $1.45B | $1.48B | $1.69B | $1.94B | $2.33B | $2.88B | $3.18B |
| Growth (year over year) | +9.1% | +7.9% | −5.7% | −11.0% | +2.4% | +13.6% | +14.9% | +20.2% | +23.6% | +10.6% |
| Gross profit | $1.53B | $1.62B | $1.43B | $1.33B | $1.38B | $1.56B | $1.78B | $2.07B | $2.57B | $2.80B |
| Gross margin | 95.5% | 93.9% | 87.8% | 91.9% | 92.7% | 92.7% | 92.2% | 88.9% | 89.2% | 87.9% |
| Operating income | $1.06B | $814.9M | $805.4M | −$187.6M | $593.6M | $555.9M | $979.7M | $1.18B | $1.38B | $1.49B |
| Operating margin | 66.4% | 47.2% | 49.5% | −12.9% | 40.0% | 33.0% | 50.6% | 50.9% | 47.9% | 46.9% |
| Net income | $713.7M | $417.9M | $589.2M | −$104.5M | $514.8M | $475.8M | $727.3M | $984.8M | $1.20B | $1.33B |
| Net margin | 44.6% | 24.2% | 36.2% | −7.2% | 34.7% | 28.2% | 37.6% | 42.3% | 41.5% | 41.9% |
| EPS (diluted) | $15.25 | $9.31 | $13.39 | −$2.39 | $11.54 | $10.06 | $15.00 | $19.81 | $24.64 | $27.86 |
| Balance sheet | ||||||||||
| Cash and equivalents | $1.02B | $705.1M | $669.2M | $738.4M | $738.7M | $894.8M | $961.2M | $1.21B | $1.70B | $1.56B |
| Total assets | $2.33B | $2.88B | $3.40B | $3.91B | $4.62B | $5.17B | $6.04B | $7.17B | $7.36B | $7.88B |
| Total liabilities | $463.4M | $758.4M | $593.2M | $1.13B | $1.22B | $1.21B | $1.25B | $1.18B | $920.0M | $783.8M |
| Shareholders' equity | $1.85B | $2.10B | $2.79B | $2.78B | $3.40B | $3.96B | $4.80B | $5.98B | $6.44B | $7.10B |
| Cash flow | ||||||||||
| Operating cash flow | $643.6M | $474.2M | $778.4M | −$206.6M | $755.7M | $598.2M | $802.5M | $978.0M | $1.33B | $1.56B |
| Capital expenditure | $38.0M | $86.3M | $184.4M | $83.7M | $59.3M | $120.8M | $138.8M | $230.4M | $246.5M | $520.5M |
| Free cash flow | $605.6M | $387.9M | $594.0M | −$290.3M | $696.4M | $477.4M | $663.7M | $747.6M | $1.08B | $1.04B |
| Share buybacks | $500.0M | $250.0M | — | — | — | — | $0 | $0 | $1.00B | $1.00B |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $748.9M | $735.9M | $794.4M | $798.6M | $799.5M | $790.2M | $781.5M | $783.3M |
| Growth (year over year) | +22.9% | +19.7% | +17.2% | +11.7% | +6.8% | +7.4% | −1.6% | −1.9% |
| Gross profit | $665.8M | $660.0M | $701.9M | $711.0M | $698.6M | $686.8M | $648.1M | $683.8M |
| Gross margin | 88.9% | 89.7% | 88.4% | 89.0% | 87.4% | 86.9% | 82.9% | 87.3% |
| Operating income | $343.1M | $357.7M | $382.8M | $364.5M | $388.5M | $356.7M | $325.8M | $330.8M |
| Operating margin | 45.8% | 48.6% | 48.2% | 45.6% | 48.6% | 45.1% | 41.7% | 42.2% |
| Net income | $309.1M | $301.3M | $322.2M | $309.5M | $338.7M | $364.3M | $274.9M | $333.0M |
| Net margin | 41.3% | 40.9% | 40.6% | 38.8% | 42.4% | 46.1% | 35.2% | 42.5% |
| EPS (diluted) | $6.39 | $6.23 | $6.63 | $6.41 | $7.16 | $7.66 | $5.82 | $7.27 |
| Balance sheet | ||||||||
| Cash and equivalents | $1.55B | $1.70B | $1.90B | $1.59B | $1.34B | $1.56B | $1.28B | $1.80B |
| Total assets | $7.12B | $7.36B | $7.74B | $7.91B | $7.35B | $7.88B | $6.71B | $7.22B |
| Total liabilities | $1.02B | $920.0M | $936.7M | $734.4M | $760.9M | $783.8M | $813.1M | $819.8M |
| Shareholders' equity | $6.10B | $6.44B | $6.81B | $7.17B | $6.59B | $7.10B | $5.90B | $6.40B |
| Cash flow | ||||||||
| Operating cash flow | $377.2M | $341.2M | $461.2M | $191.7M | $562.1M | $346.2M | $463.3M | $313.6M |
| Capital expenditure | $76.5M | $86.7M | $74.9M | $62.2M | $210.5M | $172.9M | $100.8M | $108.0M |
| Free cash flow | $300.7M | $254.5M | $386.3M | $129.5M | $351.6M | $173.3M | $362.5M | $205.6M |
| Share buybacks | $0 | $0 | $0 | $0 | $1.00B | $0 | $1.50B | $0 |
From United Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About United Therapeutics
United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire.
Source: Wikipedia — United Therapeutics
- Headquarters
- Silver Spring, Maryland From SEC filings, Oct 2026
Recent News (1)
Other Health Care companies to compare with UTHR
- UPB Upstream Bio Inc
- UPC Universe Pharmaceuticals
- URGN Urogen Pharma LTD
- USPH US Physical Therapy Inc
- UTMD Utah Medical Products Inc
- VALN Valneva
- VCEL Vericel Corp
- VCNX Vaccinex